PD-1 immunotherapy better than chemo alone as first line lung cancer treatment

13:16 EDT 3 Jun 2018 | ecancermedicalscience

Dr Lopes presents results at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting that show front line pembrolizumab surpassed chemotherapy for lung cancer patients whose tumours had PD-L1 expression and no EGFR/ALK rearrangements. For...

PD-1 immunotherapy better than chemo alone as first line lung cancer treatment

More From BioPortfolio on "PD-1 immunotherapy better than chemo alone as first line lung cancer treatment"